XRTX (XORTX Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XRTX XORTX Therapeutics Inc XRTX
32 GF Score
Price $2.40
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

XRTX
32GF Score
XORTX Therapeutics Inc XRTX
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XORTX Therapeutics Business Description

Other Exchanges ANU:GermanyXRTX:Canada
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
32GF Score

Get the complete analysis for XRTX

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price